Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 519 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... May 7, 2024 Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... September 24, 2021 Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... September 4, 2025 20 years on: how we’ve decreased cancer death rates December 17, 2022 Load more HOT NEWS A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... Tattoo Artist Helps Breast Cancer Survivors Cover Their Port Scars Listening to Patient Narratives New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer...
